PLGA (75:25)PLGA (75:25) (Synonyms: 乳酸/乙醇酸共聚物 (75:25)
poly(lactic-co-glycolic acid) (75:25))
MedChemExpress (MCE)
HY-B2247A
34346-01-5
乳酸/乙醇酸共聚物 (75:25)
乳酸/乙醇酸共聚物 (75:25)
poly(lactic-co-glycolic acid) (75:25))
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
美国大陆的室温;其他地方可能有所不同。
PLGA (75:25) 是一种低毒的,具有生物相容性和生物降解性的活性分子控释载体,可在生物体内达到缓释的作用。PLGA (75:25) 由 75% 聚乳酸 (PLA) 和 25% 聚乙醇酸 (PGA) 的聚合而成。PLGA (75:25) 已被广泛用于活性分子、蛋白质和其他各种大分子如 DNA、RNA和肽的输送研究。
PLGA(75:25)是一种低毒性、生物相容性和可生物降解的可控药物递送载体,可在生物体内实现缓慢释放。PLGA(75:25)是75%聚乳酸(PLA)和25%聚乙醇酸(PGA)的共聚物。PLGA(75:25)已被广泛研究用作药剂、蛋白质和各种其他大分子(如DNA、RNA和肽)的递送载体[1][2][3]。
PLGA 75:25 (0.03-5 mg/mL;72 小时) 仅在浓度过高而无法用于临床时影响 Calu-3 细胞的活力[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
PLGA 75:25 (40 mg/kg Risperidone (PLGA 75:25 as a drug delivery carrier);sc;single) 具有良好的45天缓释活性[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| | | | | | | | |
| | | | | |
[1]. Mura S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine. 2011
6:2591-605.
[2]. D'Souza S, et al. Development of Risperidone PLGA Microspheres. J Drug Deliv. 2014
2014:620464.
[3]. Makadia HK, et al. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel). 2011 Sep 1
3(3):1377-1397.
[4]. Chung TW, Tsai YL, Hsieh JH, Tsai WJ. Different ratios of lactide and glycolide in PLGA affect the surface property and protein delivery characteristics of the PLGA microspheres with hydrophobic additives. J Microencapsul. 2006
23(1):15-27.